Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine

This study has been completed.
Information provided by:
University Hospital, Basel, Switzerland Identifier:
First received: February 18, 2009
Last updated: December 1, 2010
Last verified: December 2010
The purpose of this study is the determination of blood concentration and the effectiveness of esketamine after nasal application.

Condition Intervention Phase
Drug: esketamine hydrochloride
Phase 1

Study Type: Interventional
Official Title: Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine

Further study details as provided by University Hospital, Basel, Switzerland:

Study Start Date: February 2009
Study Completion Date: October 2009
Arms Assigned Interventions
Experimental: Esketamine Drug: esketamine hydrochloride


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • male
  • age ≥18 years ≤ 45 years
  • healthy
  • non-smoking
  • BMI 18-27

Exclusion Criteria:

  • abuse of drugs
  • known or supposed hypersensitivity and/or contraindication against ketamine or additives
  • participation of another clinical study within the last 30 days
  • chronic obstructed nose breathing or nasal polyps
  • dug allergy
  • blood donation within the last two months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00847418

Clinical Research Center, University Hospital Basel
Basel, BS, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Principal Investigator: Manuel Haschke, MD Clinical Pharmacology and Toxicology, University Hospital Basel
  More Information

Responsible Party: Qualified Person, Stefanie Deuster, PhD., Hospital Pharmacy, University Hospital Basel, Switzerland. Identifier: NCT00847418     History of Changes
Other Study ID Numbers: EKBB 351/08, 2009DR1015
Study First Received: February 18, 2009
Last Updated: December 1, 2010

Keywords provided by University Hospital, Basel, Switzerland:
Anesthetics, Dissociative processed this record on May 24, 2017